


Supplementary Figure 5



Supplementary Figure 5. Histologic analysis of organs harvested from mice bearing OVCAR3 tumors immediately post therapy and after four weeks off-therapy. (A) n= 17 Mice were injected with 1.0x10⁶ OVCAR3 tumor cells. After two weeks, one mouse was randomly selected and euthanized pre-therapy to confirm tumor take. (B) The remaining mice bearing OVCAR3 xenografts were randomized to receive either vehicle or ReACp53 15mg/kg 3x/week IP (n=8 per treatment). After 4 weeks of therapy, residual tumors were harvested from n=3 mice/treatment (immediately post therapy cohort). Intraperitoneal (IP) cells were collected by pelvic wash. Representative pelvic washing cell pellet shown for one mouse per treatment in Figure 2, remaining n=2 mice/treatment harvested shown. Representative images for metastatic organ implants (red arrows) shown for each treatment group. (C) The remaining n=5 mice/treatment were released off-therapy for an additional 4 weeks (release cohort). IP tumors were collected and analyzed by pelvic wash. Representative images of pelvic washing shown in Figure 2, remaining cell pellets n=4 mice/treatment shown. Representative images for metastatic organ implants (red arrows) shown for each treatment group.